Literature DB >> 12804638

Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications.

Monica Pallis1, Claire Seedhouse, Martin Grundy, Nigel Russell.   

Abstract

STAT5 phosphorylation has been noted in 69-95% of AML cases by Western blotting. We used flow cytometry to measure phosphorylated STAT5 on a semi-quantitative scale. The method was validated on K562 cells, which constitutively express phosphorylated STAT5, but lose this when BCR-abl tyrosine kinase activity is blocked by STI571. Phosphorylated STAT5 was found to measure 2.22+/-0.09 relative fluorescence units (RFU) falling to 0.925+/-0.005RFU in the presence of STI571. Phosphorylated STAT5 expression was 0.99 to 2.09RFU in 28 primary AML samples. There was no logical cut-off point between positive and negative fluorescence. FLT3 internal tandem duplications, found in 11/28 samples, were not significantly associated with the level of phosphorylated STAT5 expression. We conclude that STAT5 phosphorylation can be measured sensitively by flow cytometry in AML and that its expression should not be dichotomised as present or absent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804638     DOI: 10.1016/s0145-2126(03)00012-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD.

Authors:  Kevin D Bunting; Xiu Yan Xie; Ilka Warshawsky; Eric D Hsi
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

Review 2.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Authors:  Margaret E M Van Meter; Ernesto Díaz-Flores; Joehleen A Archard; Emmanuelle Passegué; Jonathan M Irish; Nikesh Kotecha; Garry P Nolan; Kevin Shannon; Benjamin S Braun
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

4.  Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Authors:  James Marvin; Suchitra Swaminathan; Geoffrey Kraker; Amy Chadburn; James Jacobberger; Charles Goolsby
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

5.  BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.

Authors:  W-H Lin; W-T Jiaang; C-W Chen; K-J Yen; S-Y Hsieh; S-C Yen; C-P Chen; K-Y Chang; C-Y Chang; T-Y Chang; Y-L Huang; T-K Yeh; Y-S Chao; C-T Chen; J T-A Hsu
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

6.  Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals.

Authors:  Amrie C Grammer; Randy Fischer; Olivia Lee; Xuan Zhang; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2004-02-05       Impact factor: 5.156

7.  Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.

Authors:  Wen-Hsing Lin; Teng-Kuang Yeh; Weir-Torn Jiaang; Kuei-Jung Yen; Chun-Hwa Chen; Chin-Ting Huang; Shih-Chieh Yen; Shu-Yi Hsieh; Ling-Hui Chou; Ching-Ping Chen; Chun-Hsien Chiu; Li-Chun Kao; Yu-Sheng Chao; Chiung-Tong Chen; John T-A Hsu
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.